Abstract
Anthracyclines, such as doxorubicin and idarubicin, remain an important class of chemotherapeutic agents. Unfortunately, their efficacy in treating cancer is limited by a cumulative dose-dependent cardiotoxicity, which can cause irreversible heart failure. In this review, we discuss the pathogenesis and incidence of anthracycline-induced cardiotoxicity as well as methods to detect, prevent and treat the condition.
MeSH terms
-
Anthracyclines / adverse effects*
-
Antineoplastic Agents / adverse effects*
-
Cardiotoxins / adverse effects*
-
Doxorubicin / adverse effects*
-
Heart Failure / chemically induced
-
Heart Failure / prevention & control
-
Humans
-
Idarubicin / adverse effects*
-
Prevalence
-
Risk Factors
-
Ventricular Dysfunction, Left / chemically induced*
-
Ventricular Dysfunction, Left / prevention & control
Substances
-
Anthracyclines
-
Antineoplastic Agents
-
Cardiotoxins
-
Doxorubicin
-
Idarubicin